Fertility and Sterility
Volume 94, Issue 4 , Pages 1296-1301 , September 2010

Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects

  • Emily J. Blake, M.D.

      Affiliations

    • Ferring Pharmaceuticals, Inc., Parsippany, New Jersey
    • ,
  • Paul M. Norris, M.D.

      Affiliations

    • Division of Gynecology, Department of Obstetrics and Gynecology, Miller School of Medicine, University of Miami, Miami, Florida
    • ,
  • Sally Faith Dorfman, M.D., MSHSA.

      Affiliations

    • Ferring Pharmaceuticals, Inc., Parsippany, New Jersey
    • Corresponding Author InformationReprint requests: Sally Faith Dorfman, M.D., MSHSA., Ferring Pharmaceuticals, Inc., 4 Gatehall Drive, Third Floor, Parsippany, NJ 07054 (FAX: 973-796-1663).
    • ,
  • James Longstreth, Ph.D.

      Affiliations

    • Longstreth & Associates, Inc., Mundelein, Illinois
    • ,
  • Vladimir I. Yankov, M.D.

      Affiliations

    • Ferring Pharmaceuticals, Inc., Parsippany, New Jersey

Received 27 February 2008 ,Revised 7 May 2009 ,Accepted 3 June 2009.

References 

  1. Toner JP. The luteal phase: luteal support protocols. In:  Gardner DK,  Weissmann A,  Howles CM,  Shohan Z editor. Textbook of assisted reproductive techniques. London: Taylor & Francis; 2004;p. 639–650
  2. Pabuccu R, Akar ME. Luteal phase support in assisted reproductive technology. Curr Opin Obstet Gynecol. 2005;17:277–281
  3. Penzias AS. Luteal phase support. Fertil Steril. 2002;77:318–323
  4. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update. 2000;6:139–148
  5. Whitehead MI, Townsend PT, Gill DK, Collins WP, Campbell S. Absorption and metabolism of oral progesterone. Br Med J. 1980;280:825–827
  6. Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12:1073–1079
  7. Levine H, Watson N. Comparison of the pharmacokinetics of Crinone™ 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril. 2000;73:516–521
  8. Simon JA, Robinson DE, Andrews MC, Hildebrand JR, Rocci ML, Blake RE, et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril. 1993;60:26–33
  9. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI. Dose dependant effects of oral progesterone on the oestrogenised postmenopausal endometrium. Br Med J (Clin Res Ed). 1983;287:1241–1245
  10. Devroey P, Braekmans P, Camus M, Khan I, Smitz J, Staessen C, et al. Embryo donation in patients with primary ovarian failure. Hum Reprod. 1988;3(Suppl 2):85–87
  11. Kuhle JW, Swoboda B. Gluteal compartment syndrome after intramuscular gluteal injection. Z Orthop Ihre Grenzgeb. 1999;137:366–367
  12. Kimzey LM, Gumowski J, Merriam GR, Grimes GJ, Nelson LM. Absorption of micronized progesterone from a nonliquefying vaginal cream. Fertil Steril. 1991;56:995–996
  13. Archer DF, Fahy GE, Viniegra-Sibal A, Anderson FD, Snipes W, Foldesy RG. Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am J Obstet Gynecol. 1995;173:471–478
  14. Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of oral and vaginally administered progesterone. Fertil Steril. 1991;56:1034–1039
  15. Cicinelli E, de Ziegler D, Buletti C, Matteo MG, Schonauer LM, Galantino P. Direct transport of progesterone from vagina to uterus. Obstet Gynecol. 2000;95:403–406
  16. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62:485–490
  17. Jobanputra K, Toner JP, Denoncourt R, Gibbons WE. Crinone 8% (90 mg) given once daily for progesterone replacement therapy in donor egg cycles. Fertil Steril. 1999;72:980–984
  18. Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101
  19. Chantilis SJ, Zeitoun KM, Patel SI, John DA, Madziar VA, McIntire DD. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–829
  20. Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–1288
  21. Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky EH. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization–embryo transfer cycles. Fertil Steril. 2001;76:1144–1149
  22. Kleinstein J. Efficacy and tolerability of vaginal progesterone capsules (Utrogest ™ 200) compared with progesterone gel (Crinone ™ 8%) for luteal phase support during assisted reproduction. Fertil Steril. 2005;83:1641–1649
  23. Levine H. Luteal support in IVF using the novel vaginal progesterone gel Crinone 8%: results of an open-label trial in 1184 women from 16 U.S. centers. Fertil Steril. 2000;74:836–837
  24. Fanchin R, de Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol. 1997;90:396–401
  25. Doody KJ, Schnell VL, Foulk RA, Miller CE, Kolb BA, Blake EJ, et al. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective in-vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertil Steril. 2009;91:1012–1017
  26. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed.. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005;260
  27. Csapo AL, Pulkkinen MO, Wiest WG. Effects of lutectomy and progesterone replacement in early pregnant patients. Am J Obstet Gynecol. 1973;115:759–765
  28. Schneider MA, Davies MC, Honour JW. The timing of placental competence in pregnancy after oocyte donation. Fertil Steril. 1993;59:1059–1064
  29. Azuma K, Calderon I, Besanko M, Maclachlan V, Healy D. Is the luteo-placental shift a myth? Analysis of low progesterone levels in successful ART pregnancies. J Clin Endocrinol Metab. 1993;77:195–198

 E.J.B. has nothing to disclose. P.M.N. has nothing to disclose. S.F.D. has nothing to disclose. J.L. has nothing to disclose. V.I.Y. has nothing to disclose.

 Supported by Ferring Pharmaceuticals, Inc., of Parsippany, NJ.

PII: S0015-0282(09)01311-9

doi: 10.1016/j.fertnstert.2009.06.014

Fertility and Sterility
Volume 94, Issue 4 , Pages 1296-1301 , September 2010

Article Tools

* Image Usage & Resolution